Review

rabbit anti tpx2 (Novus Biologicals)

Novus Biologicals is a verified supplier

Novus Biologicals manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Novus Biologicals rabbit anti tpx2
Rabbit Anti Tpx2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 47 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+tpx2/TPX2+Antibody/pm41876446-467-4-8
Average 93 stars, based on 47 article reviews

rabbit anti tpx2 - by Bioz Stars, 2026-11

93/100 stars

Images

other:

Article Title: The ATC12 small molecule inhibits the Aurora-A/TPX2 interaction and impairs the proliferation of breast cancer cells
Article Snippet: Antibodies were as follows: rabbit anti-TPX2 (NB500-179, 1:1000, Novus Biologicals, Cambridge, UK), mouse anti-Aurora-A (610939, 0.5 μg/ml, BD Transduction Laboratories, Meylan, France), rabbit anti-PARP (9542, 1:1000, Cell Signaling Technology, Danvers, Massachusetts, USA), rabbit anti-phospho-Aurora-A (Thr288)/Aurora B (Thr232)/Aurora C (Thr198) (2914, 1:1000, Cell Signaling Technology, Danvers, Massachusetts, USA), mouse anti-α-Tubulin (T9026, 1:1000, Sigma Aldrich-Merck KGaA, Darmstadt, Germany), and mouse anti-GAPDH (SC-32233, 1:1000, Santa Cruz Biotechnology, Dallas, Texas, USA).

Article Title: The ATC12 small molecule inhibits the Aurora-A/TPX2 interaction and impairs the proliferation of breast cancer cells.
Article Snippet: Antibodies were as follows: rabbit anti-TPX2 (NB500-179, 1:1000, Novus Biologicals, Cambridge, UK), mouse anti-Aurora-A (610939,0.5 μg/ml, BD Transduction Laboratories, Meylan, France), rabbit anti-PARP (9542, 1:1000, Cell Signaling Technology, Danvers, Massachusetts, USA), rabbit anti-phospho-Aurora A (Thr288)/Aurora B (Thr232)/ Aurora C (Thr198) (2914, 1:1000, Cell Signaling Technology, Danvers, Massachusetts, USA), mouse anti-α-Tubulin (T9026, 1:1000, Sigma Aldrich-Merck KGaA, Darmstadt, Germany), and mouse anti-GAPDH (SC-32233, 1:1000, Santa Cruz Biotechnology, Dallas, Texas, USA).

Article Title: The ATC12 small molecule inhibits the Aurora-A/TPX2 interaction and impairs the proliferation of breast cancer cells.
Article Snippet: Primary antibodies were as follows: rabbit anti-phosphoAurora-A (Thr288; #3079S, 1:100, Cell Signaling Technology, Danvers, Massachusetts, USA); mouse antiα-tubulin (T5168, 2 μg/ml, Sigma Aldrich-Merck KGaA, Darmstadt, Germany); mouse anti-Aurora-A (610939, 0.5 μg/ml, BD Transduction Laboratories, Meylan, France); rabbit anti-TPX2 (NB500-179, 1:1500, Novus Biologicals, Cambridge, UK); rabbit anti-p21 (2947, 1:1000, Cell Signaling Technology, Danvers, Massachusetts, USA).

Article Title: AurkA nuclear localization is promoted by TPX2 and counteracted by protein degradation.
Article Snippet: Antibodies were as follows: rabbit anti-TPX2 (1:1,000; Novus Biologicals), mouse anti-Aurora-A (0.5 μg/ml; BD Transduction Laboratories), rabbit anti-pAurora-A (Thr288) (3079 clone C39D8, 1:100; Cell Signaling Technology, Inc.), andmouse anti-GAPDH (SC-32233, 1: 1,000; Santa Cruz Biotechnology).

Article Title: AurkA nuclear localization is promoted by TPX2 and counteracted by protein degradation
Article Snippet: Primary antibodies were as follows: mouse anti-Aurora-A (610939, 0.5 μ g/ml; BD Transduction Laboratories); rabbit anti-TPX2 (NB500-179, 1:1,500; Novus Biologicals); rabbit anti-Cep170 (final bleed, 1:100 ( )); rabbit anti-lamin B1 (ab16048, 1 μ g/ml; Abcam); rabbit anti-PCNA (ab18197, 2 μ g/ml; Abcam); and mouse anti-myc tag (clone 4A6, 05-724, 2 μ g/ml; Merck Millipore).

Article Title: AurkA nuclear localization is promoted by TPX2 and counteracted by protein degradation
Article Snippet: Antibodies were as follows: rabbit anti-TPX2 (1:1,000; Novus Biologicals), mouse anti-Aurora-A (0.5 μ g/ml; BD Transduction Laboratories), rabbit anti-pAurora-A (Thr288) (3079 clone C39D8, 1:100; Cell Signaling Technology, Inc.), and mouse anti-GAPDH (SC-32233, 1:1,000; Santa Cruz Biotechnology).

Article Title: The ATC12 small molecule inhibits the Aurora-A/TPX2 interaction and impairs the proliferation of breast cancer cells
Article Snippet: Primary antibodies were as follows: rabbit anti-phospho-Aurora-A (Thr288; #3079S, 1:100, Cell Signaling Technology, Danvers, Massachusetts, USA); mouse anti-α-tubulin (T5168, 2 μg/ml, Sigma Aldrich-Merck KGaA, Darmstadt, Germany); mouse anti-Aurora-A (610939, 0.5 μg/ml, BD Transduction Laboratories, Meylan, France); rabbit anti-TPX2 (NB500-179, 1:1500, Novus Biologicals, Cambridge, UK); rabbit anti-p21 (2947, 1:1000, Cell Signaling Technology, Danvers, Massachusetts, USA).

Article Title: AurkA nuclear localization is promoted by TPX2 and counteracted by protein degradation.
Article Snippet: Primary antibodieswere as follows:mouse anti-AuroraA (610939, 0.5 μg/ml; BD Transduction Laboratories); rabbit anti-TPX2 (NB500-179, 1:1,500; Novus Biologicals); rabbit anti-Cep170 (final bleed, 1:100 (65)); rabbit anti-lamin B1 (ab16048, 1 μg/ml; Abcam); rabbit antiPCNA (ab18197, 2 μg/ml; Abcam); and mouse anti-myc tag (clone 4A6, 05-724, 2 μg/ml; Merck Millipore).

Image Search Results

SVs disrupt gene expression in UTUC. A. Variant Manhattan plot showing genes whose expression is significantly correlated with the proximity of SSV breakpoints. The upper panel displays the number of samples with SSV breakpoints near each gene (y-axis) across the genome (x-axis). Labelled genes indicate significant SSV-expression associations. The lower panel presents genome-wide CNV G-scores for comparison. B. Bar plots quantifying the number of genes with SSV-associated expression changes, before and after adjusting for CNV effects. The reduction in significant associations after adjustment highlights SSVs with independent effects on gene expression. C. Pie charts illustrating the distribution of SSV types among expression-altering breakpoints (left), and the genomic distribution of DEL breakpoints (right), emphasising the prevalence of intronic deletions in gene expression regulation. D. Pie chart showing the proportion of expression-altering SSV breakpoints that are associated with ecDNA. E. Bar plot showing 14 genes with significantly higher SSV frequency in MI-UTUC than in NMI-UTUC (Fisher's exact test). The number of samples with SSVs in each gene is shown for both MI and NMI groups. F. Upper panel: Receiver operating characteristic curves evaluating the predictive performance of TPX2 SSV status for UTUC. AUC values and corresponding p-values are indicated. Lower panel: Box plots showing expression levels of TPX2 in patients with and without SSVs. G. Expression levels of TPX2 in MI and NMI groups across UTUC transcriptomic datasets from published data (BCM, MAD, WCM). H. Representative images of IHC in UTUC samples with TPX2 related SSV (left panel), without TPX2 SSVs (middel panel). Scale bar, 500 μm (left), 100 μm (right). Right panel: A semi-quantitative modified IHC score was calculated in IHC of TPX2 as staining intensity (0–3) × staining extent (0–3), yielding a score range of 0–9. Each dot represents one case; boxes indicate the median and interquartile range.

Journal: eBioMedicine

Article Title: Somatic structural variants drive upper tract urothelial carcinoma muscle invasiveness via activation of TPX2 transcription

doi: 10.1016/j.ebiom.2026.106182

Figure Lengend Snippet: SVs disrupt gene expression in UTUC. A. Variant Manhattan plot showing genes whose expression is significantly correlated with the proximity of SSV breakpoints. The upper panel displays the number of samples with SSV breakpoints near each gene (y-axis) across the genome (x-axis). Labelled genes indicate significant SSV-expression associations. The lower panel presents genome-wide CNV G-scores for comparison. B. Bar plots quantifying the number of genes with SSV-associated expression changes, before and after adjusting for CNV effects. The reduction in significant associations after adjustment highlights SSVs with independent effects on gene expression. C. Pie charts illustrating the distribution of SSV types among expression-altering breakpoints (left), and the genomic distribution of DEL breakpoints (right), emphasising the prevalence of intronic deletions in gene expression regulation. D. Pie chart showing the proportion of expression-altering SSV breakpoints that are associated with ecDNA. E. Bar plot showing 14 genes with significantly higher SSV frequency in MI-UTUC than in NMI-UTUC (Fisher's exact test). The number of samples with SSVs in each gene is shown for both MI and NMI groups. F. Upper panel: Receiver operating characteristic curves evaluating the predictive performance of TPX2 SSV status for UTUC. AUC values and corresponding p-values are indicated. Lower panel: Box plots showing expression levels of TPX2 in patients with and without SSVs. G. Expression levels of TPX2 in MI and NMI groups across UTUC transcriptomic datasets from published data (BCM, MAD, WCM). H. Representative images of IHC in UTUC samples with TPX2 related SSV (left panel), without TPX2 SSVs (middel panel). Scale bar, 500 μm (left), 100 μm (right). Right panel: A semi-quantitative modified IHC score was calculated in IHC of TPX2 as staining intensity (0–3) × staining extent (0–3), yielding a score range of 0–9. Each dot represents one case; boxes indicate the median and interquartile range.

Article Snippet: For immunohistochemistry, TPX2 was detected using a rabbit polyclonal anti-TPX2 antibody (HUABIO, ER65201; RRID Tags AB_3731329), generated against a synthesised peptide derived from human TPX2 (aa 301–350), and recommended for IHC-P (1:100–1:300).

Techniques: Gene Expression, Variant Assay, Expressing, Genome Wide, Comparison, Modification, Staining

An upstream structural variant interval enhances TPX2 expression and promotes invasive phenotypes in urothelial cancer cells. A. Schematic representation of somatic structural variants (SSVs) surrounding the TPX2 locus. A recurrent duplication event localised to the chr20:31000852–31001508 interval upstream of TPX2 was identified. This region contains eight tandem repeats of a 171-bp sequence. Two unique sgRNAs were designed to delete a 683-bp fragment spanning this interval. B. PCR and gel electrophoresis validation of CRISPR ribonucleoprotein (RNP)-mediated deletion of the TPX2 upstream interval in 5637 cells. The main band corresponding to the intact region (1025 bp) was markedly attenuated in TPX2-upstream knockout cells. (C, D). Quantitative RT-PCR (C) and Western blot (D) analyses showing that deletion of the chr20:31000852–31001508 interval significantly reduced TPX2 mRNA and protein expression in 5637 cells. (E, F) Quantitative RT-PCR (E) and Western blot (F) analyses demonstrating that transfection of a PCR-derived fragment corresponding to the TPX2 upstream interval increased TPX2 expression compared with control cells. G. Schematic of the dual-luciferase reporter construct in which the TPX2 promoter region (2331 bp, including exon 1) was cloned upstream of the Renilla luciferase (Rluc) gene in the psiCHECK-2 vector. H. Dual-luciferase reporter assay showing that co-transfection of the TPX2 promoter reporter with PCR-derived fragments from the chr20:31000852–31001508 interval significantly increased Rluc activity compared with co-transfection with a random 1-kb DNA fragment, indicating enhancer-like activity of this interval. (I, J) Western blot validation of TPX2 knockout (KO) (I) and TPX2 overexpression (OE) (J) in 5637 cells. (K, L) Wound-healing (K) and transwell migration and invasion assays (L) demonstrating that TPX2 knockout significantly impaired cell motility and invasive capacity. Scale bar = 1 mm in K, scale bar = 200 um in L. (M, N) Wound-healing (M) and transwell migration and invasion assays (N) showing that TPX2 overexpression markedly enhanced migratory and invasive properties of 5637 cells. Scale bar = 1 mm in M, scale bar = 200 um in N. Data are presented as mean ±SD (n = 3). Two-sided Mann-Whitney U test was used for comparisons between two groups. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001). O. KEGG pathway enrichment analysis of genes downregulated upon TPX2 knockout (TPX2_KO vs. NC_KO). P. Gene set enrichment analysis (GSEA) of transcriptomic changes induced by amplification of the TPX2 upstream interval (Ups_OE vs. NC_OE). Pathways related to EMT, cell adhesion, and extracellular matrix remodelling were significantly enriched.

Journal: eBioMedicine

Article Title: Somatic structural variants drive upper tract urothelial carcinoma muscle invasiveness via activation of TPX2 transcription

doi: 10.1016/j.ebiom.2026.106182

Figure Lengend Snippet: An upstream structural variant interval enhances TPX2 expression and promotes invasive phenotypes in urothelial cancer cells. A. Schematic representation of somatic structural variants (SSVs) surrounding the TPX2 locus. A recurrent duplication event localised to the chr20:31000852–31001508 interval upstream of TPX2 was identified. This region contains eight tandem repeats of a 171-bp sequence. Two unique sgRNAs were designed to delete a 683-bp fragment spanning this interval. B. PCR and gel electrophoresis validation of CRISPR ribonucleoprotein (RNP)-mediated deletion of the TPX2 upstream interval in 5637 cells. The main band corresponding to the intact region (1025 bp) was markedly attenuated in TPX2-upstream knockout cells. (C, D). Quantitative RT-PCR (C) and Western blot (D) analyses showing that deletion of the chr20:31000852–31001508 interval significantly reduced TPX2 mRNA and protein expression in 5637 cells. (E, F) Quantitative RT-PCR (E) and Western blot (F) analyses demonstrating that transfection of a PCR-derived fragment corresponding to the TPX2 upstream interval increased TPX2 expression compared with control cells. G. Schematic of the dual-luciferase reporter construct in which the TPX2 promoter region (2331 bp, including exon 1) was cloned upstream of the Renilla luciferase (Rluc) gene in the psiCHECK-2 vector. H. Dual-luciferase reporter assay showing that co-transfection of the TPX2 promoter reporter with PCR-derived fragments from the chr20:31000852–31001508 interval significantly increased Rluc activity compared with co-transfection with a random 1-kb DNA fragment, indicating enhancer-like activity of this interval. (I, J) Western blot validation of TPX2 knockout (KO) (I) and TPX2 overexpression (OE) (J) in 5637 cells. (K, L) Wound-healing (K) and transwell migration and invasion assays (L) demonstrating that TPX2 knockout significantly impaired cell motility and invasive capacity. Scale bar = 1 mm in K, scale bar = 200 um in L. (M, N) Wound-healing (M) and transwell migration and invasion assays (N) showing that TPX2 overexpression markedly enhanced migratory and invasive properties of 5637 cells. Scale bar = 1 mm in M, scale bar = 200 um in N. Data are presented as mean ±SD (n = 3). Two-sided Mann-Whitney U test was used for comparisons between two groups. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001). O. KEGG pathway enrichment analysis of genes downregulated upon TPX2 knockout (TPX2_KO vs. NC_KO). P. Gene set enrichment analysis (GSEA) of transcriptomic changes induced by amplification of the TPX2 upstream interval (Ups_OE vs. NC_OE). Pathways related to EMT, cell adhesion, and extracellular matrix remodelling were significantly enriched.

Techniques: Variant Assay, Expressing, Sequencing, Nucleic Acid Electrophoresis, Biomarker Discovery, CRISPR, Knock-Out, Quantitative RT-PCR, Western Blot, Transfection, Derivative Assay, Control, Luciferase, Construct, Clone Assay, Plasmid Preparation, Reporter Assay, Cotransfection, Activity Assay, Over Expression, Migration, MANN-WHITNEY, Amplification

scRNA-seq reveals TPX2 e xpression in proliferative tumour cell populations and associated pathways. A. UMAP visualisation of single-cell transcriptomic data from UTUC, identifying 20 distinct cell clusters. B. UMAP plot highlighting TPX2 expression, showing enrichment in cycling T cells, cycling epithelial cells, and cycling macrophages. Colour intensity corresponds to TPX2 expression levels. C. Dot plot displaying the percentage of cells expressing TPX2 (dot size) and the average TPX2 expression level (dot colour) across different cell types in patients with MI-UTUC and NMI-UTUC. Asterisks indicate statistically significant differences in expression between MI and NMI for specific cell types (two-sided Wilcoxon rank-sum test, Bonferroni-adjusted P values, ∗P < 0.05, ∗∗∗∗P < 0.001). D. KEGG pathway enrichment analysis of genes significantly upregulated in TPX2 -positive cycling epithelial cells compared with TPX2 -negative counterparts. Dot size represents the number of genes in each pathway; colour indicates the adjusted p-value of enrichment. E. Cell–cell communication heatmap showing the number of predicted ligand-receptor interactions among major cell types in the UTUC tumour microenvironment. Cell types are arranged on both axes, with senders (ligand-expressing cells) on the y-axis and receivers (receptor-expressing cells) on the x-axis. The intensity of red reflects the total number of interactions between each cell pair, as indicated by the colour scale. (F, G) Outgoing (F) and incoming (G) signalling patterns among cell types in the UTUC tumour microenvironment. Heatmaps show the relative strength of ligand-receptor signalling pathways based on CellChat analysis. Colour intensity indicates relative communication strength; bar plots on the top and right summarise overall pathway activity across cell types.

Journal: eBioMedicine

Article Title: Somatic structural variants drive upper tract urothelial carcinoma muscle invasiveness via activation of TPX2 transcription

doi: 10.1016/j.ebiom.2026.106182

Figure Lengend Snippet: scRNA-seq reveals TPX2 e xpression in proliferative tumour cell populations and associated pathways. A. UMAP visualisation of single-cell transcriptomic data from UTUC, identifying 20 distinct cell clusters. B. UMAP plot highlighting TPX2 expression, showing enrichment in cycling T cells, cycling epithelial cells, and cycling macrophages. Colour intensity corresponds to TPX2 expression levels. C. Dot plot displaying the percentage of cells expressing TPX2 (dot size) and the average TPX2 expression level (dot colour) across different cell types in patients with MI-UTUC and NMI-UTUC. Asterisks indicate statistically significant differences in expression between MI and NMI for specific cell types (two-sided Wilcoxon rank-sum test, Bonferroni-adjusted P values, ∗P < 0.05, ∗∗∗∗P < 0.001). D. KEGG pathway enrichment analysis of genes significantly upregulated in TPX2 -positive cycling epithelial cells compared with TPX2 -negative counterparts. Dot size represents the number of genes in each pathway; colour indicates the adjusted p-value of enrichment. E. Cell–cell communication heatmap showing the number of predicted ligand-receptor interactions among major cell types in the UTUC tumour microenvironment. Cell types are arranged on both axes, with senders (ligand-expressing cells) on the y-axis and receivers (receptor-expressing cells) on the x-axis. The intensity of red reflects the total number of interactions between each cell pair, as indicated by the colour scale. (F, G) Outgoing (F) and incoming (G) signalling patterns among cell types in the UTUC tumour microenvironment. Heatmaps show the relative strength of ligand-receptor signalling pathways based on CellChat analysis. Colour intensity indicates relative communication strength; bar plots on the top and right summarise overall pathway activity across cell types.

Techniques: Single Cell, Expressing, Activity Assay

Spatial transcriptomic delineation of TPX2 positive epithelial cells and their tumour microenvironmental interactions in UTUC. A. Representative haematoxylin and eosin (H&E)-stained sections (left) and corresponding spatial transcriptomic cell-type annotations (right) from MI (upper) and NMI (lower)-UTUC biopsy, scale bar = 1 mm. Spatial spots were annotated by integrating spatial transcriptomics with single-cell reference datasets, revealing the spatial organisation of epithelial tumour populations and diverse TME components. B. Box plots showing TPX2 expression levels across major spatially defined cell types in MI-UTUC biopsy. TPX2 expression was significantly enriched in basal epithelial tumour cells and specific urothelial tumour subpopulations compared with immune and stromal compartments (∗∗∗∗, P < 0.0001; Wilcoxon rank-sum test). C. Bar plot comparing the proportion of TPX2 positive spots across spatial cell types between MI- and NMI-UTUC samples. TPX2 positive epithelial tumour populations were markedly enriched in MI-UTUC relative to NMI-UTUC. D. Box plots showing average epithelial mesenchymal transition (EMT) signature scores in spatial neighbours of TPX2 positive versus TPX2 negative epithelial tumour cells. Neighbourhoods surrounding TPX2 positive cells exhibited significantly higher EMT associated transcriptional activity (P = 3.33 × 10 −3 ; Wilcoxon rank-sum test), indicating localisation of TPX2 positive tumour cells within invasion-promoting microenvironments. E. Bar plot showing log2 fold changes of EGFR- and EPHA2-associated ligand expression in spatial neighbours of TPX2 positive compared with TPX2 negative epithelial tumour cells.

Journal: eBioMedicine

Article Title: Somatic structural variants drive upper tract urothelial carcinoma muscle invasiveness via activation of TPX2 transcription

doi: 10.1016/j.ebiom.2026.106182

Figure Lengend Snippet: Spatial transcriptomic delineation of TPX2 positive epithelial cells and their tumour microenvironmental interactions in UTUC. A. Representative haematoxylin and eosin (H&E)-stained sections (left) and corresponding spatial transcriptomic cell-type annotations (right) from MI (upper) and NMI (lower)-UTUC biopsy, scale bar = 1 mm. Spatial spots were annotated by integrating spatial transcriptomics with single-cell reference datasets, revealing the spatial organisation of epithelial tumour populations and diverse TME components. B. Box plots showing TPX2 expression levels across major spatially defined cell types in MI-UTUC biopsy. TPX2 expression was significantly enriched in basal epithelial tumour cells and specific urothelial tumour subpopulations compared with immune and stromal compartments (∗∗∗∗, P < 0.0001; Wilcoxon rank-sum test). C. Bar plot comparing the proportion of TPX2 positive spots across spatial cell types between MI- and NMI-UTUC samples. TPX2 positive epithelial tumour populations were markedly enriched in MI-UTUC relative to NMI-UTUC. D. Box plots showing average epithelial mesenchymal transition (EMT) signature scores in spatial neighbours of TPX2 positive versus TPX2 negative epithelial tumour cells. Neighbourhoods surrounding TPX2 positive cells exhibited significantly higher EMT associated transcriptional activity (P = 3.33 × 10 −3 ; Wilcoxon rank-sum test), indicating localisation of TPX2 positive tumour cells within invasion-promoting microenvironments. E. Bar plot showing log2 fold changes of EGFR- and EPHA2-associated ligand expression in spatial neighbours of TPX2 positive compared with TPX2 negative epithelial tumour cells.

Techniques: Staining, Spatial Transcriptomics, Single Cell, Expressing, Activity Assay

Shared genes and pathways between TPX2 WGCNA modules. ( a ) Upset plot showing shared DEGs between WGCNA modules related to TPX2 as a hub gene, including M3 (prim/norm), M2 (mHSPC/prim) and M1 (mCRPC/mHSPC). A total of 22 DEGs were shared among all three modules. ( b ) Heatmap of the unsupervised hierarchical clustering analysis on the variance-stabilized transformed (VST) expression of shared DEGs among all TPX2 modules as in (a). Each row corresponds to a single gene, whereas each column corresponds to a single sample. ( c ) Upset plot showing shared REACTOME pathways between modules as in (a). ( d ) A total of 20 pathways were shared among all three modules as in (a). The circle size is the gene ratio for each shared pathway in each comparison.

Journal: Scientific Reports

Article Title: Unravelling TPX2-centered co-expression networks as key drivers of aggressive prostate cancer

doi: 10.1038/s41598-025-27704-4

Figure Lengend Snippet: Shared genes and pathways between TPX2 WGCNA modules. ( a ) Upset plot showing shared DEGs between WGCNA modules related to TPX2 as a hub gene, including M3 (prim/norm), M2 (mHSPC/prim) and M1 (mCRPC/mHSPC). A total of 22 DEGs were shared among all three modules. ( b ) Heatmap of the unsupervised hierarchical clustering analysis on the variance-stabilized transformed (VST) expression of shared DEGs among all TPX2 modules as in (a). Each row corresponds to a single gene, whereas each column corresponds to a single sample. ( c ) Upset plot showing shared REACTOME pathways between modules as in (a). ( d ) A total of 20 pathways were shared among all three modules as in (a). The circle size is the gene ratio for each shared pathway in each comparison.

Article Snippet: TMA FFPE blocks were cut into 3 μm thick sections and manual IHC staining was performed using a Rabbit Anti-Human TPX2 antibody (11741-1-AP, Proteintech) diluted at 1:200.

Techniques: Transformation Assay, Expressing, Comparison

Validation of TPX2 protein expression. ( a ) Representative microscopic images of IHC staining of normal (norm), primary PCa (prim) and lymph node metastatic (met) PCa samples. Brown nuclear staining indicates TPX2 expression. Sections were counterstained with hematoxilin (blue color). ( b ) Protein expression levels indicated by H-scores, calculated from tissue microarrays containing 154 norm, 194 prim and 54 met tissue core biopsies. ( c ) Kaplan Meyer survival curves for high (red) and low (blue) expression levels of TPX2 . The expression cutoff (6.38) was determined by recursive partitioning. Hazard ratio (HR) including 95% confidence interval (CI) were determined by Cox proportional hazards analysis.

Journal: Scientific Reports

Article Title: Unravelling TPX2-centered co-expression networks as key drivers of aggressive prostate cancer

doi: 10.1038/s41598-025-27704-4

Figure Lengend Snippet: Validation of TPX2 protein expression. ( a ) Representative microscopic images of IHC staining of normal (norm), primary PCa (prim) and lymph node metastatic (met) PCa samples. Brown nuclear staining indicates TPX2 expression. Sections were counterstained with hematoxilin (blue color). ( b ) Protein expression levels indicated by H-scores, calculated from tissue microarrays containing 154 norm, 194 prim and 54 met tissue core biopsies. ( c ) Kaplan Meyer survival curves for high (red) and low (blue) expression levels of TPX2 . The expression cutoff (6.38) was determined by recursive partitioning. Hazard ratio (HR) including 95% confidence interval (CI) were determined by Cox proportional hazards analysis.

Article Snippet: TMA FFPE blocks were cut into 3 μm thick sections and manual IHC staining was performed using a Rabbit Anti-Human TPX2 antibody (11741-1-AP, Proteintech) diluted at 1:200.

Techniques: Biomarker Discovery, Expressing, Immunohistochemistry, Staining

Univariate Cox proportional hazards analysis of TPX2 -associated genes. Forest plot shows univariate Cox regression analysis of six TPX2 -associated genes ( TPX2 , MYBL2 , EXO1 , RRM2 , CENPA , and NEIL3 ), using biochemical recurrence (BCR) as the outcome. Hazard ratios (HR) with 95% confidence intervals (CI) are displayed for high vs. low expression groups, as defined by recursive partitioning (RP) cutpoints. After FDR correction, all six genes showed significant higher risk of BCR.

Journal: Scientific Reports

Article Title: Unravelling TPX2-centered co-expression networks as key drivers of aggressive prostate cancer

doi: 10.1038/s41598-025-27704-4

Figure Lengend Snippet: Univariate Cox proportional hazards analysis of TPX2 -associated genes. Forest plot shows univariate Cox regression analysis of six TPX2 -associated genes ( TPX2 , MYBL2 , EXO1 , RRM2 , CENPA , and NEIL3 ), using biochemical recurrence (BCR) as the outcome. Hazard ratios (HR) with 95% confidence intervals (CI) are displayed for high vs. low expression groups, as defined by recursive partitioning (RP) cutpoints. After FDR correction, all six genes showed significant higher risk of BCR.

Article Snippet: TMA FFPE blocks were cut into 3 μm thick sections and manual IHC staining was performed using a Rabbit Anti-Human TPX2 antibody (11741-1-AP, Proteintech) diluted at 1:200.

Techniques: Expressing

Review

rabbit anti tpx2 (Novus Biologicals)

Structured Review

Images

Related Articles

other:

Similar Products

Image Search Results